Observational studies suggest that treatment with methylphenidate often results in a reduction in height gain. On average, the reduction in height amounts to approximately 1 cm/year during the first 1-3 years of treatment. However, it is not clear whether these effects persist in the long-term. Furthermore, it could be that ADHD is associated with growth problems even in the absence of stimulant medication. Treatment with methylphenidate is also related to weight loss. This weight loss might represent, at least in part, a shift towards the optimum weight from a position of previous obesity. These uncertainties will be addressed by ADDUCE.
In addition, these effects on growth might also be expected to influence the onset of puberty. ADDUCE will investigate the timing of puberty and identify whether there is any evidence for an impact of long-term methylphenidate treatment on the timing of puberty.
Furthermore, other factors might influence growth effects associated with methylphenidate. Socio-economic status is potentially important as are age at starting medication, parental height, problems at birth and other medication amongst others.
In order to address these issues, specific operative procedures have been prepared to accurately measure children’s height and weight, sexual maturation and bone age and a group of experts in paediatric endocrinology and auxology, in the environment and in pharmacovigilance is identified to discuss and implement the specific research strategies on the stimulant effect of growth.
The fifth ADDUCE Newsletter is now available!
Here, you can read about the finalisation of the project,
the European Medicines Agency and General Assembly meetings
and the dissemination of the results!
The fourth ADDUCE Newsletter is available!
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study
- the long-term cardiascular effects of methylphenidate use
Also, you can read about the future plans of the project!
More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!
Did you participate in the ADDUCE studies and are you curious about the latest news on the project?
Here you can find some information!
News for children, April 2015
News for adolescents, April 2015
News for parents, April 2015
The third ADDUCE Newsletter is available!
- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
- the long-term cardiovascular effects of methylphenidate use: study design and participation
and much more in the ADDUCE Newsletter 3, March 2015
WP3: prospective open-label methylphenidate
- WP8: long-term cardiovascular effects of methylphenidate use
and much more in the ADDUCE Newsletter 2, February 2013
16 - 19 OCTOBER 2016:
4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care
17 & 18 APRIL 2016:
ADDUCE Consortium meeting, London - UK
28 - 31 MAY 2015:
5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland
20 & 21 APRIL 2015:
ADDUCE Consortium meeting, Salina - Italy
21 - 24 MAY 2014:
3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders
19 & 20 MAY 2014:
ADDUCE Consortium meeting, Istanbul - Turkey
3 - 6 OCTOBER 2013:
23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders
6 - 9 JUNE 2013:
4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy
4 & 5 JUNE 2013:
ADDUCE Consortium meeting, Milan - Italy
6 & 7 JUNE 2012:
ADDUCE Consortium meeting, Cagliari - Italy
23 MAY 2012:
2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain